Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7884211
Dimeric small molecule potentiators of apoptosis
granted -
US 7884066
NELL-1 enhanced bone mineralization
granted -
US 7883892
Swine multipotent adult progenitor cells
granted -
US 7879576
Marine actinomycete taxon for drug and fermentation product discovery
granted -
US 7879798
Composition for indolent wound healing and methods of use therefor
granted -
US 7879792
Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
granted -
US 7879548
Detection of biomarkers for neuropsychiatric disorders
granted -
US 7879801
Compositions comprising cell-impermeant duramycin derivatives
granted -
US 7879370
Composition of which chief ingredient is polysaccharides having an immunoregulatory function
granted -
US 7879324
Fusion molecules and methods for treatment of immune diseases
granted -
US 7879334
Fusion molecules and treatment of IgE-mediated allergic diseases
granted -
US 7875276
Urinary tract tissue graft compositions and methods for producing same
granted -
US 7875284
Methods of manufacturing and modifying taxane coatings for implantable medical devices
granted -
US 7875598
Compositions useful for the treatment of microbial infections
granted -
US 7871814
Recombinant bicistronic flaviviruses and methods of use thereof
granted -
US 7871775
Compositions and methods for the identification, assessment, prevention and therapy of human cancers
granted -
US 7871620
Immunoliposomes that optimize internationalization into target cells
granted -
US 7871778
Methods of diagnosing endometriosis
granted -
US 7867476
Method and materials for use in diagnosing viral myocarditis
granted -
US 7867512
Cross-linked polymersomes and related encapsulating membranes
granted -
US 7867275
Coated implantable medical device method
granted -
US 7862605
Coated implantable medical device
granted -
US 7862821
Recombinant vaccine against bluetongue virus
granted -
US 7863414
Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
granted -
US 7863415
Amino acid and peptide conjugates of amiloride and methods of use thereof
granted -
US 7863275
Uses of tetrahydrobiopterin and derivatives thereof
granted -
US 7862811
Protease inhibition for prevention or treatment of heart failure
granted -
US 7858592
Interfering RNAs against the promoter region of P53
granted -
US 7858657
Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
granted -
US 7858123
Inorganic materials for hemostatic modulation and therapeutic wound healing
granted -
US 7858349
Anti-cancer compounds
granted -
US 7854932
Immunogenic compositions comprising progastrin and uses thereof
granted -
US 7851465
Compositions and methods relating to novel compounds and targets thereof
granted -
US 7850961
Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist
granted -
US 7850970
Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
granted -
US 7851228
Methods for screening agents that modulate presenilin activity and A-Ξ² production
granted -
US 7847084
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 7846895
Selectively targeted antimicrobial peptides and the use thereof
granted -
US 7846664
Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
granted -
US 7846426
Compositions and methods for treating and preventing cardiomyopathy and heart disease
granted -
US 7842667
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
granted -
US 7838556
Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
granted -
US 7838691
Palmerolides: methods of preparation and derivatives thereof
granted -
US 7838511
Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
granted -
US 7838571
Photopolymers and use in dental restorative materials
granted -
US 7838253
Methods of modulating cold sensory perception via a cold- and menthol-sensitive receptor (CMR1)
granted -
US 7838289
Assay utilizing multipotent adult stem cells
granted -
US 7834150
Isolated cold-and-menthol-sensitive receptor (CMR1)
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory